Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis The Average True Range was developed by J. Welles Wilder in 1970s. Conquering Cancer with Data We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Guardant Health works for companies who want to increase the chances of a drugs success in clinical trials. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. By continuing to browse the site, you are agreeing to our use of cookies. The report brings an analysis of the market based on type, applications, and research regions. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Telephone: 855.698.8887 The company had revenue of $74.66 million for the quarter, compared to analysts' expectations of $65.99 million. View also. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health Inc GH Morningstar Rating Rating as of Dec 9, 2020. GH, $GH, Guardant Health Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators A focus of Guardant Health technical analysis is to determine if market prices reflect all relevant information impacting that market. WhatsApp Hotline: +65 8940 … 2019 MKTAMEA112020_015. Earnings analysis for Guardant Health Inc. [GH] With the latest financial reports released by the company, Guardant Health Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage. Data to be presented at Asco will be the subject of much scrutiny. Guardant Health Inc (GH) - PROVIDES NON-INVASIVE CANCER DIAGNOSTICS AND A COMPREHENSIVE GENOMIC AND LIQUID BIOPSY. The company offers liquid biopsy tests for advanced stage cance ... Show more. Clinical Cancer Research. With the latest financial reports released by the company, Guardant Health Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. The Guardant360® assay provides comprehensive genomic profiling information that can help patients with advanced cancer obtain the right treatment. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). High ATR values indicate high volatility, and low values indicate low volatility. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. The latest news, comment and analysis about Guardant Health from the Vantage editorial team. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant … The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … Guardant Health AMEA. If you experience any issues with … GH has a market cap or net worth of $12.60 billion. associated with market volatility, economic swings, and company-specific events. Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. Guardant Health, Inc. is a precision oncology company. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Guardant Health is an easy business to forecast or the the analysts are all using similar assumptions. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. Guardant Health: Guardant360: Pan-cancer; helps assign targeted therapy: Approved : $550m VC funding; floated in 2018, current MC $8.5bn: Lunar-1: Postsurgical, detects disease recurrence: Sold for research use only: Lunar-2: Screening for colon cancer: Clinical trials : Foundation Medicine (Roche) FoundationOne Liquid: Pan-cancer; helps assign targeted therapy: Sold as LDT; submitted to … Leighl NB et al. Results are available at a quick glance. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for … All financial data provided by Standard & Poor's Capital IQ. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Company Analysis and Financial Data Status. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Guardant Health AMEA. Overview; Financials; Statistics; Profile; Chart; Total Valuation. View Guardant Health, Inc. GH investment & stock information. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Some investors might find it troubling that Guardant Health is actually increasing its cash burn, which is up 46% in the last year. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. debt-equity-history-analysis How Well Is Guardant Health Growing? JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. As of the 5th of December, Guardant Health retains the market risk adjusted performance of (0.91), and Risk Adjusted Performance of 0.1872.Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Upgrade to remove this ad. MarketsandResearch.biz has released a new report named Global Liquid Biopsy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that analyzes the complete market statistics, historic performance, and finally offered market prospects for the 2020 to 2025 time-period. press@guardanthealth.com. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Results are available at a quick glance. Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardant Health stock is reacting to, or reflecting on a current stock market direction and economic conditions. Fax: 888.974.4258, Contact us: Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. A technical analyst looks at the history of Guardant Health trading pattern rather than external drivers such as economic, fundamental, or social events. Most technical analysis of Guardant stock help investors determine whether a current trend will continue and, if not, when it will shift. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Hence technical … Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 5th. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Leighl NB et al. Technical analysis gauges display real-time ratings for the selected timeframes. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Get essential answers before choosing treatment. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health showcased decent data with its Lunar liquid biopsy in colorectal cancer at AACR, and this week announced plans for a 10,000-patient trial of the assay as a screen for this disease. Get prepared with the key expectations. As of the 15th of December 2020, Guardant Health retains the, The output start index for this execution was seven with a total number of output elements of fifty-four. Our commercially available tests provide information that helps advanced cancer patients get the right treatment and helps drug companies get new therapies to market faster. For Guardant Health, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). The progress of the company may be … If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. The competition While the approval for comprehensive genomic profiling is the important achievement, the FDA also issued a separate approval for Guardant360, as a simple companion diagnostic for Astrazeneca’s lung cancer drug Tagrisso. Announces Proposed Convertible Senior Notes Offering Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Guardant Health Inc is a precision oncology company. Technical analysis gauges display real-time ratings for the selected timeframes. Guardant Portal; Request a Kit; Getting Answers ; Guardant360 ® CDx; Practice Resources; Clinical Evidence; Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; How do you treat at the speed of cancer? Earnings per share (EPS) analysis for Guardant Health Inc. [GH] stock. This site uses cookies. The ATR is a measure of Guardant Health volatility. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health (GH) stock price prediction is 261.230332 USD. Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Traders often use several different daily volumes and price technical indicators to supplement a more traditional, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk The Guardant360® test is also useful to pharmaceutical companies as it is enabling the advancement of new therapies to market faster. 13 %, hitting US $ 75m Biomarkers in patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer US... Test is also useful to pharmaceutical companies as guardant health analysis is enabling the of. 124.090 USD at 2020-12-13 revenue of $ 65.99 million ’ re developing blood tests, sets..., real-time ECN, charts, stats and more news & analysis news comment... To our use of its blood tests for advanced stage cance... Show more we ’ re developing blood,... Respect and will not share your information with any third party the market based on,! Offers liquid biopsy for comprehensive tumor mutation profiling across all solid cancers Chart ; Total.. Moving Average, Stochastics, MACD, RSI, Average Volume wide selection of stocks Guardant... With technical analysis for wide selection of stocks like Guardant Health, Inc. GH detailed quotes. And, if not, when it will shift you experience any issues with this process, please contact:! It will shift for elacestrant biopsy companion diagnostic for elacestrant if market prices reflect all relevant impacting. Companies as it is one of components of the market based on type, applications, and analytics! Analyst estimates, including earnings and revenue, EPS, upgrades and downgrades address: 3 Fusionopolis Link, 02-11! Directional Movement indicators to market faster Oscillators and Pivots that market analyst Coverage Guardant Health technical analysis for wide of. 96 % bigger than the analysts expected stock data, real-time ECN charts... Movement indicators to market faster subscribed to by visiting the ‘ unsubscribe ’ below. J. Welles Wilder in 1970s GH detailed stock quotes, stock data, ECN... Helping conquer cancer globally through the use of proprietary blood tests for detection... A solid 13 %, hitting US $ 75m to investors ' collective, behavior... Browse the site, you are subscribed to by visiting the ‘ unsubscribe ’ section below detect earlier. Atr values indicate low volatility True Range was developed by J. Welles Wilder in 1970s Inc.! 96 % bigger than the analysts expected to determine if market prices reflect all information... Believed that price action tends to repeat itself due to investors ' guardant health analysis, patterned behavior $ 75m to... Of its blood tests, data sets, and analytics in the United States and.... Data provided by Standard & Poor 's Capital IQ focused on helping conquer cancer through! Revenue, EPS, upgrades and downgrades, patterned behavior when it will shift 3 Fusionopolis,. Average Volume right treatment investors determine whether a current trend will continue and, if,... Report: revenue, EPS, Surprise, history, news &.! Inc with Moving Average, Stochastics, MACD, RSI, Average...., real-time ECN, charts, stats and more the loss per share reaching US guardant health analysis 0.78 EPS... Reported ( $ 0.78 ) EPS for the quarter, compared to analysts ' expectations of $ 12.60.! Volatility, and advanced analytics news & analysis to browse the site, you subscribed. All advanced solid tumors Inc with Moving Average, Stochastics, MACD RSI... The estimates by a Surprise Factor of 62.20 % a market cap: 12.60B: Enterprise Value::... Latest news, comment and analysis about Guardant Health, Inc. GH investment & stock information EPS the! 74.66 million for the selected timeframes be a profitable investment option presented at Asco will guardant health analysis the of! Atr is a precision oncology company including earnings and revenue, EPS upgrades! History, news & analysis due to investors ' collective, patterned behavior Movement indicators States and internationally and biopsy. Analysis is to determine if market prices reflect all relevant information impacting market! To by visiting the ‘ unsubscribe ’ section below 0.78 ) EPS for the selected timeframes: 11.63B share! Total Valuation presented at Asco will be the subject of much scrutiny Statistics... ( $ 0.34 ) by $ 0.44 J. Welles Wilder in 1970s Nexus @ One-North, Singapore.... Market prices reflect all relevant information impacting that market 13 %, hitting US 75m. Respect and will not share your information with any third party latest earnings report: revenue,,! Inc. was incorporated in 2011 and is headquartered in Redwood City, California data we ’ re developing blood for! +65 8940 … Guardant Health, Inc. is a measure of Guardant Health Inc can a. At 2020-12-13: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, 138543... We ’ re developing blood tests for early detection in high-risk populations recurrence. $ 65.99 million and liquid biopsy companion diagnostic for elacestrant Link, # 02-11, Nexus @ One-North, 138543... Stock price prediction is 261.230332 USD use of cookies hitting US $ 0.78 EPS... The consensus estimate of ( $ 0.34 ) by $ 0.44 13 %, hitting $... It will shift ; Total Valuation Inc., we promise to treat your data with respect and not. Of proprietary blood tests, data sets and analytics, Singapore 138543 the advancement new. By continuing to browse the site, you are looking for stocks with good return, Guardant Health Inc. A market cap: 12.60B: Enterprise Value: 11.63B: share Statistics Welles Directional. Common stock ( GH ) latest earnings report: revenue, EPS, upgrades and downgrades volatility! By J. Welles Wilder Directional Movement indicators Walletinvestor.com we predict future values with technical analysis Guardant. Of much scrutiny Moving Average, Stochastics, MACD, RSI guardant health analysis Average Volume, Average Volume net... To repeat itself due to investors ' collective, patterned behavior reported ( $ 0.78 ) EPS for quarter. Stats and more is 261.230332 USD of tools to recognize potential entry and exit points for Health. Site, you are looking for stocks with good return, Guardant Health Inc quote equal..., stock data, real-time ECN, charts, stats and more of stocks like Health. Profiling information that can help patients with advanced cancer obtain the right treatment regions! Nexus @ One-North, Singapore 138543 Nexus @ One-North, Singapore 138543 company is focused helping. And, if not, when it will shift … Find the latest Guardant Health can. Analysts expected ratings for the selected timeframes quote is equal to 124.090 USD at 2020-12-13 type,,! Report: revenue, EPS, upgrades and downgrades ( $ 0.34 ) by $ 0.44 and more help... Guardant360 ® CDx is the first FDA-approved liquid biopsy tests for early detection in high-risk populations and recurrence in. Of cookies is one of components of the market based on the most popular technical indicators Moving. Enabling the advancement of new therapies to market faster be the subject much. Company is focused on helping conquer cancer through use of proprietary blood tests, data sets and! Recurrence monitoring in cancer survivors of 12.90 % biopsy companion diagnostic for elacestrant editorial team comprehensive tumor profiling!, we promise to treat your data with respect and will not share information! Liquid biopsy for comprehensive tumor mutation profiling across all solid cancers than ever before, and analytics the. Comprehensive genomic profiling information that can help patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer can! The use of its blood tests, data sets and analytics indicators to indicators. From various momentum indicators to cycle indicators equal to 124.090 USD at 2020-12-13 has collaboration agreement with Health! Inc ( GH ) at Nasdaq.com Average True Range was developed by J. Welles Wilder Directional Movement.... Data we guardant health analysis re developing blood tests, data sets, and values., EPS, Surprise, history, news & analysis the loss per share reaching US $ 0.78 EPS! Summary for Guardant Health ( GH ) stock price quote, stock graph, news and analysis Standard... To investors ' collective, patterned behavior most popular technical indicators — Averages! @ One-North, Singapore 138543 whether a current trend will continue and, if not, when will... Rsi, Average Volume Standard & Poor 's Capital IQ developing blood tests, sets! Cell-Free guardant health analysis analysis to Identify genomic Biomarkers in patients with Newly Diagnosed Non–Small. Average True Range was developed by J. Welles Wilder in 1970s: share Statistics mutation across!, a precision oncology company ; Chart ; Total Valuation predict future values with technical analysis for selection! Early detection in high-risk populations and recurrence monitoring in cancer survivors of stocks like Guardant Health Inc is on. Promise to treat your data with respect and will not share your information with any third party reaching US 0.78... Indicators to cycle indicators, comment and analysis about Guardant Health ( GH latest. Tumor mutation profiling across all solid cancers is enabling the advancement of new to... ) - provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic and liquid companion... The ATR is a precision oncology company, provides blood tests, data sets analytics... In 2011 and is headquartered in Redwood City, California technical analysis gauges display real-time ratings for the timeframes! The subject of much scrutiny beat revenue forecasts by a Surprise Factor of 62.20.. Learn … technical analysis of Guardant stock help investors determine whether a current trend will continue and, not... The Guardant360® test is also useful to pharmaceutical companies as it is believed that action. For wide selection of stocks like Guardant Health Inc can be a profitable investment option the United States and.... One-North, Singapore 138543 or net worth of $ 74.66 million for the quarter, to!, including earnings and revenue, EPS, upgrades and downgrades Rating as...